BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 6241752)

  • 21. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.
    Coller BS
    J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
    Inbal A; Kornbrot N; Harrison P; Randi AM; Sadler JE
    Thromb Haemost; 1993 Dec; 70(6):1058-62. PubMed ID: 8165601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet--von Willebrand factor interactions in type IIB von Willebrand's disease.
    Holmberg L; Kristoffersson AC; Lamme S; Nilsson IM; Awidi A; Solum NO
    Scand J Haematol; 1985 Sep; 35(3):305-14. PubMed ID: 3877338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Von Willebrand factor-dependent agglutination of washed fixed human platelets by insoluble collagen isolated from bovine aorta.
    Perret BA; Furlan M; Jenö P; Beck EA
    J Lab Clin Med; 1986 Mar; 107(3):244-52. PubMed ID: 3005453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of platelet activation on the agglutination of platelets by von Willebrand factor.
    Mills DC; Hunchak K; Karl DW; Kirby EP
    Mol Pharmacol; 1990 Feb; 37(2):271-7. PubMed ID: 2154674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormality of glycoprotein Ib in two cases of "pseudo"-von Willebrand's disease.
    Bryckaert MC; Pietu G; Ruan C; Tobelem G; Girma JP; Meyer D; Larrieu MJ; Caen JP
    J Lab Clin Med; 1985 Oct; 106(4):393-400. PubMed ID: 2931492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet adhesion to collagen in subtypes of type I von Willebrand's disease is dependent on platelet von Willebrand factor.
    d'Alessio P; Zwaginga JJ; de Boer HC; Federici AB; Rodeghiero F; Castaman G; Mariani G; Mannucci PM; de Groot PG; Sixma JJ
    Thromb Haemost; 1990 Oct; 64(2):227-31. PubMed ID: 2125373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease.
    Green D; Potter EV
    J Lab Clin Med; 1976 Jun; 87(6):976-86. PubMed ID: 778313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of ristocetin-induced platelet agglutination by vancomycin.
    Moake JL; Cimo PL; Peterson DM; Roper P; Natelson EA
    Blood; 1977 Sep; 50(3):397-406. PubMed ID: 301760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane fluidity and platelet aggregation: dibucaine permits ristocetin-induced platelet aggregation with low-molecular-weight von Willebrand multimers.
    Gjønnaess E; Solum NO; Brosstad F
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):395-405. PubMed ID: 1420815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
    Gaucher C; de Romeuf C; Rauïs-Morret M; Corazza F; Fondu P; Mazurier C
    Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variant forms of von Willebrand's disease: type IIA, type IIB and platelet-type von Willebrand's disease.
    Takahashi H
    Nihon Ketsueki Gakkai Zasshi; 1984 Dec; 47(8):1678-89. PubMed ID: 6335811
    [No Abstract]   [Full Text] [Related]  

  • 35. [Type 2B and pseudo type 2B Von Willebrand disease; a report of three cases].
    Guermazi S; Conard J; Samama MM; Dellagi K
    Pathol Biol (Paris); 2006 Apr; 54(3):159-65. PubMed ID: 16176858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination.
    Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL
    J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that von Willebrand factor is not required for the clotting of plasma in the presence of platelets and kaolin (Hardisty-Hutton test).
    McPherson J; Soberano ME; Macdonald C; Zucker MB
    Thromb Haemost; 1984 Apr; 51(2):272-4. PubMed ID: 6429885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.
    Allain JP; Cooper HA; Wagner RH; Brinkhous KM
    J Lab Clin Med; 1975 Feb; 85(2):318-28. PubMed ID: 234499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.
    De Marco L; Mazzuccato M; Grazia Del Ben M; Budde U; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1987 Aug; 80(2):475-82. PubMed ID: 3038958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.